GlassScriptPhysician profile
Aaron James Dupre
NPI 1922706621
$7,198.29
in general payments reported to CMS, 2019-2025
27 companies · $2,737 in 2025
The $2,737 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,452 · 2024: $3,009 · 2025: $2,737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,198.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,265.71 | 2023-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $885.57 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $659.28 | 2023-2025 | Caplyta |
| Corium, LLC | $421.24 | 2023-2025 | Azstarys |
| Lundbeck LLC | $404.17 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $388.12 | 2023-2025 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $384.84 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $348.26 | 2023-2025 | Sublocade, Perseris |
| Neurocrine Biosciences, INC. | $346.07 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $316.98 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $240.39 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $221.76 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Janssen Scientific Affairs, LLC | $196.73 | 2024-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $158.53 | 2024-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $154.90 | 2023-2024 | Jornay Pm |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $132.50 | 2024 | Tavneos |
| Braeburn INC. | $129.33 | 2024-2025 | Brixadi |
| Tris Pharma INC | $123.70 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Almatica Pharma LLC | $90.25 | 2024-2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $60.77 | 2023-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $57.41 | 2024 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $53.75 | 2023-2025 | Trintellix |
| Vertical Pharmaceuticals, LLC | $45.07 | 2024 | Relexxii |
| Neos Therapeutics, LP | $37.31 | 2023 | Adzenys Xr-Odt |
| Avion Pharmaceuticals | $32.58 | 2023 | Methylphenidate Hydrochloride |
| Sage Therapeutics, LLC | $23.85 | 2023 | |
| Merck Sharp & Dohme LLC | $19.22 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Dupre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.